Passage Bio Stock Performance
| PASG Stock | USD 11.08 0.22 2.03% |
On a scale of 0 to 100, Passage Bio holds a performance score of 8. The company holds a Beta of -0.2, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Passage Bio are expected to decrease at a much lower rate. During the bear market, Passage Bio is likely to outperform the market. Please check Passage Bio's expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Passage Bio's historical price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Passage Bio are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Passage Bio reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 21.7 M | |
| Total Cashflows From Investing Activities | 54.9 M |
Passage Bio Relative Risk vs. Return Landscape
If you would invest 803.00 in Passage Bio on September 30, 2025 and sell it today you would earn a total of 283.00 from holding Passage Bio or generate 35.24% return on investment over 90 days. Passage Bio is currently generating 0.6279% in daily expected returns and assumes 5.6982% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Passage, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Passage Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Passage Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Passage Bio, and traders can use it to determine the average amount a Passage Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1102
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PASG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Passage Bio is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Passage Bio by adding it to a well-diversified portfolio.
Passage Bio Fundamentals Growth
Passage Stock prices reflect investors' perceptions of the future prospects and financial health of Passage Bio, and Passage Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Passage Stock performance.
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | 6.08 M | ||||
| Shares Outstanding | 3.18 M | ||||
| Price To Book | 1.11 X | ||||
| EBITDA | (62.09 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 25.48 M | ||||
| Debt To Equity | 0.11 % | ||||
| Book Value Per Share | 9.79 X | ||||
| Cash Flow From Operations | (47.96 M) | ||||
| Earnings Per Share | (14.62) X | ||||
| Total Asset | 102.41 M | ||||
| Retained Earnings | (659.24 M) | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
About Passage Bio Performance
By analyzing Passage Bio's fundamental ratios, stakeholders can gain valuable insights into Passage Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Passage Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Passage Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.Things to note about Passage Bio performance evaluation
Checking the ongoing alerts about Passage Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Passage Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Passage Bio is way too risky over 90 days horizon | |
| Passage Bio appears to be risky and price may revert if volatility continues | |
| Passage Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39. |
- Analyzing Passage Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Passage Bio's stock is overvalued or undervalued compared to its peers.
- Examining Passage Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Passage Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Passage Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Passage Bio's stock. These opinions can provide insight into Passage Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |